Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Interventional × Miransertib × Clear all

Phase

Status

Completed 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 519 Specimen Handling 410 Carboplatin 401 Magnetic Resonance Spectroscopy 378 Cisplatin 365 Cyclophosphamide 352 Radiotherapy 292 Gemcitabine 278 Bevacizumab 268 Paclitaxel 263 Biopsy 226 Drug Therapy 218 venetoclax 208 Capecitabine 204 fludarabine 202 Oxaliplatin 202 Nivolumab 201 Docetaxel 187 Injections 186 Fluorouracil 179 Dexamethasone 164 Radiosurgery 154 Rituximab 147 Pemetrexed 145 Standard of Care 131 durvalumab 129 atezolizumab 124 tislelizumab 122 Doxorubicin 122 Leucovorin 119

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡